Previous 10 | Next 10 |
The U.S. Military HIV Research Program has launched a Phase 2 clinical trial in Thailand to evaluate ImmunityBio’s (IBRX) interleukin-15 (IL-15) superagonist Anktiva (also called N-803) in combination with antiretroviral therapy ((ART)) during acute HIV infection as an experimental the...
Phase 2 Study Sponsored by U.S. Military HIV Research Program, Thai Red Cross AIDS Research Centre ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Insti...
As testing accelerates, company boosts manufacturing speed, output, and quality control with over 2 trillion cryopreserved NK cells ready for off-the-shelf use ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced it has administered...
ImmunityBio and NantKwest have merged, creating a juggernaut pre-clinical and clinical pipeline. The share price has been weak since the merger, however I remain bullish at these prices. The company has an impressive COVID-19 vaccine candidate that could be best-in-class and possibly ...
Galectin Therapeutics (GALT) +27% as its belapectin + Keytruda enhances tumor response in melanoma, head/neck cancer.Bit Digital (BTBT) +17%.UTStarcom Holdings (UTSI) +14%.Greenwich LifeSciences (GLSI) +15% after update on GP2 phase III clinical trial sesign.Moleculin Biotech (MBRX)...
Announcing preliminary Phase 1 data, ImmunityBio (IBRX) has highlighted the potential of its experimental dual antigen hAd5 S + N vaccine against COVID-19 to provide long-term protection as well as immunity against the new coronavirus variants.A single subcutaneous injection of the ...
Preliminary Phase 1b findings in participants receiving the dual antigen hAd5 S + N vaccine generated Th1 dominant S and N specific T cells after a single prime subcutaneous injection The magnitude of this T cell response was equivalent to those seen for S & N T cell responses...
ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced the appointment of health innovation expert and executive Linda Maxwell, M.D., MBA, as an independent member of the company’s board of directors. The company also appointed CEO Richard...
Second-generation human adenovirus (hAd5) targeting multiple tumor associated antigens (PSA, MUC-1, Brachyury) demonstrated safety, with no dose-limiting toxicities in patients with advanced prostate cancer Positive immune activation to PSA, MUC-1, and Brachyury with 100% of 1...
ImmunityBio ([[IBRX]] +7.3%) posts positive preclinical data highlighting efficacy of the company's PD-L1 t-haNK natural killer cell-based therapy in combination with T cell-based immunotherapy against heterogeneous tumors.The study supports ImmunityBio’s hypothesis of combining N...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 01:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into ImmunityBio, Inc. (NasdaqGS: IBRX). On May 11, 2023, the Company disclosed that it had receiv...